Maximal androgen blockade for advanced prostate cancer.

Area of Science:

• Oncology
• Urology
• Cancer Research

Background:

• Prostate cancer is a leading cancer in urban India, ranking third in Delhi.
• Increased longevity leads to a rise in advanced prostate cancer cases.
• The efficacy of non-steroidal antiandrogens (MAB) in advanced prostate cancer treatment remains under investigation since the 1980s.

Purpose of the Study:

• To evaluate the clinical significance of MAB in advanced prostate cancer.
• To determine the specific patient populations who may benefit from MAB therapy.
• To assess the impact of MAB on overall survival rates.

Main Methods:

• Review of clinical trials and data concerning MAB and non-steroidal antiandrogens.
• Analysis of survival data from studies involving MAB in advanced prostate cancer.
• Identification of patient subgroups with metastatic prostate cancer who might benefit from MAB.

Main Results:

• MAB's role may be confined to preventing beta-AR reactions in patients on LHRH agonists.
• Non-steroidal antiandrogens offer a marginal increase in overall survival (3-5% at 5 years).
• Potential benefit of MAB observed in metastatic prostate cancer with low-volume disease and specific metastasis patterns (M1, excluding skull, ribs, long bones, soft tissues).

Conclusions:

• The overall survival benefit of non-steroidal antiandrogens in advanced prostate cancer is marginal.
• MAB may have a limited role in select patients with metastatic prostate cancer.
• Further research is needed to define the precise role of MAB in prostate cancer management.